Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $23 to $27.
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $23 to $27.